Diabetic Macular Edema
Conditions
Brief summary
The Health Authority - Abu Dhabi (HAAD) approved the reimbursement of the slow release FAc implant (ILUVIEN) and it is now available for the treatment of diabetic macular edema (DME) in persons who have been previously treated with a course of corticosteroids and did not have a clinically significant rise in intraocular pressure. We performed a retrospective 12-month audit to assess the efficacy and safety of the FAc implant in our clinical practice.
Detailed description
Twenty patients with pseudophakic lenses, treated with ILUVIEN, were investigated to evaluate functional and anatomical characteristics and outcomes (visual acuity \[VA; ETDRS letters score\], central macular thickness \[CMT\] and intraocular pressure \[IOP\]) at baseline, weeks 2-4 and months 3, 6 and 12 months.
Interventions
DRUG0.19 mg fluocinolone acetonide (FAc) implant
0.19 mg fluocinolone acetonide (FAc) implant
Sponsors
Sheikh Khalifa Medical City
Benha University
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Inclusion criteria
* DME * Pseudophakic
Exclusion criteria
* Other causes of macular edema. * Phakic * Know case of gaucoma
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| BCVA | 12 months | best corrected visual acuity |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| CMT | 12 months | Central Macular thickness |
| IOP | 12 months | Intraocular pressure |
Countries
United Arab Emirates
Contacts
Primary ContactAhmed Elbarky, MD
Backup ContactElbarky, MD
Outcome results
None listed